Skip to main content
Erschienen in: International Journal of Clinical Oncology 5/2015

01.10.2015 | Original Article

Oncological benefit of primary tumor resection with high tie lymph node dissection in unresectable colorectal cancer with synchronous peritoneal metastasis: a propensity score analysis of data from a multi-institute database

verfasst von: Tomohisa Furuhata, Kenji Okita, Toshihiko Nishidate, Koichi Hirata, Hirofumi Ohnishi, Hirotoshi Kobayashi, Kenjiro Kotake, Kenichi Sugihara, Study Group for Peritoneal Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum

Erschienen in: International Journal of Clinical Oncology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Peritoneal metastasis is recognized as a predictor of poor prognosis in patients with colorectal cancer, and whether surgical intervention for peritoneal metastasis has any clinical benefit has remained controversial. The purposes of this study were to identify prognostic factors in cases of unresectable colorectal cancer with synchronous peritoneal metastasis and to clarify the impacts of primary tumor resection with high tie lymph node dissection.

Methods

A multi-institutional retrospective analysis was conducted of 579 patients who underwent resection of the primary tumor for unresectable colorectal cancer with peritoneal metastasis between 1991 and 2007. For these 579 patients, clinicopathological variables were analyzed for prognostic significance using Cox proportional hazards model and propensity score analysis to mitigate the selection bias.

Results

Multivariate analysis revealed hematogenous metastasis (p < 0.001), histology of the tumor (p = 0.006), postoperative chemotherapy (p < 0.001), and lymph node dissection (p = 0.001) as independent prognostic factors. In the propensity-matched cohort, patients treated with high tie lymph node dissection showed a significantly better overall survival than those with low tie lymph node dissection (median overall survival 13.0 vs. 11.5 months; p = 0.041).

Conclusions

It is suggested that primary tumor resection with high tie lymph node dissection favorably affects survival, even in unresectable colorectal cancer with peritoneal metastasis.
Literatur
1.
Zurück zum Zitat Kotake K, Honjo S, Sugihara K et al (2003) Changes in colorectal cancer during a 20-year period: an extended report from the multi-institutional registry of large bowel cancer, Japan. Dis Colon Rectum 46:S32–S43PubMed Kotake K, Honjo S, Sugihara K et al (2003) Changes in colorectal cancer during a 20-year period: an extended report from the multi-institutional registry of large bowel cancer, Japan. Dis Colon Rectum 46:S32–S43PubMed
2.
Zurück zum Zitat Muto T, Kotake K, Koyama Y (2001) Colorectal cancer statistics in Japan: data from JSCCR registration, 1974–1993. Int J ClinOncol 6:171–176 Muto T, Kotake K, Koyama Y (2001) Colorectal cancer statistics in Japan: data from JSCCR registration, 1974–1993. Int J ClinOncol 6:171–176
3.
Zurück zum Zitat Jayne DG, Fook S, Loi C et al (2002) Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89:1545–1550CrossRefPubMed Jayne DG, Fook S, Loi C et al (2002) Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89:1545–1550CrossRefPubMed
4.
Zurück zum Zitat Kobayashi H, Enomoto M, Higuchi T et al (2010) Validation and clinical use of the Japanese classification of colorectal carcinomatosis: benefit of surgical cytoreduction even without hyperthermic intraperitoneal chemotherapy. Dig Surg 27:473–480CrossRefPubMed Kobayashi H, Enomoto M, Higuchi T et al (2010) Validation and clinical use of the Japanese classification of colorectal carcinomatosis: benefit of surgical cytoreduction even without hyperthermic intraperitoneal chemotherapy. Dig Surg 27:473–480CrossRefPubMed
5.
Zurück zum Zitat Kobayashi H, Kotake K, Funahashi K et al (2014) Clinical benefit of surgery for stage IV colorectal cancer with synchronous peritoneal metastasis. J Gastroenterol 49:646–654CrossRefPubMed Kobayashi H, Kotake K, Funahashi K et al (2014) Clinical benefit of surgery for stage IV colorectal cancer with synchronous peritoneal metastasis. J Gastroenterol 49:646–654CrossRefPubMed
6.
Zurück zum Zitat Clancy C, Burke JP, Barry M et al (2014) A meta-analysis to determine the effect of primary tumor resection for Stage IV colorectal cancer with unresectable metastases on patient survival. Ann Surg Oncol 21:3900–3908CrossRefPubMed Clancy C, Burke JP, Barry M et al (2014) A meta-analysis to determine the effect of primary tumor resection for Stage IV colorectal cancer with unresectable metastases on patient survival. Ann Surg Oncol 21:3900–3908CrossRefPubMed
7.
Zurück zum Zitat Venderbosch S, de Wilt JH, Teerenstra S et al (2011) Value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol 18:3252–3260PubMedCentralCrossRefPubMed Venderbosch S, de Wilt JH, Teerenstra S et al (2011) Value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol 18:3252–3260PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Japanese Society for Cancer of the Colon and Rectum (2009) Japanese classification of colorectal carcinoma, Second English edn. Kanehara & Co., Ltd., Tokyo Japanese Society for Cancer of the Colon and Rectum (2009) Japanese classification of colorectal carcinoma, Second English edn. Kanehara & Co., Ltd., Tokyo
9.
Zurück zum Zitat West NP, Kobayashi H, Takahashi K et al (2012) Understanding optimal colonic cancer surgery. Comparison of Japanese D3 resection and European complete excision with central vascular ligation. J Clin Oncol 30:1763–1769CrossRefPubMed West NP, Kobayashi H, Takahashi K et al (2012) Understanding optimal colonic cancer surgery. Comparison of Japanese D3 resection and European complete excision with central vascular ligation. J Clin Oncol 30:1763–1769CrossRefPubMed
10.
Zurück zum Zitat Poultsides GA, Servais EL, Saltz LB et al (2009) Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 27:3379–3384PubMedCentralCrossRefPubMed Poultsides GA, Servais EL, Saltz LB et al (2009) Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 27:3379–3384PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Nitzkorski JR, Farma JM, Watson JC et al (2011) Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection. Ann Surg Oncol 19:379–383CrossRefPubMed Nitzkorski JR, Farma JM, Watson JC et al (2011) Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection. Ann Surg Oncol 19:379–383CrossRefPubMed
12.
Zurück zum Zitat Ishihara S, Hayama T, Yamada H et al (2014) Prognostic impact of primary tumor resection and lymph node dissection in stage IV colorectal cancer with unresectable metastasis: a propensity score analysis in a multicenter retrospective study. Ann Surg Oncol 21:2949–2955CrossRefPubMed Ishihara S, Hayama T, Yamada H et al (2014) Prognostic impact of primary tumor resection and lymph node dissection in stage IV colorectal cancer with unresectable metastasis: a propensity score analysis in a multicenter retrospective study. Ann Surg Oncol 21:2949–2955CrossRefPubMed
13.
Zurück zum Zitat Hohenberger W, Weber K, Matzel K et al (2009) Standardized surgery for colonic cancer: complete mesocolic excision and central ligation––technical notes and outcome. Colorectal Dis 11:354–364CrossRefPubMed Hohenberger W, Weber K, Matzel K et al (2009) Standardized surgery for colonic cancer: complete mesocolic excision and central ligation––technical notes and outcome. Colorectal Dis 11:354–364CrossRefPubMed
14.
Zurück zum Zitat Deng L, Zhang H, Luan Y et al (2010) Accumulation of Foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin Cancer Res 16:4105–4112CrossRefPubMed Deng L, Zhang H, Luan Y et al (2010) Accumulation of Foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin Cancer Res 16:4105–4112CrossRefPubMed
Metadaten
Titel
Oncological benefit of primary tumor resection with high tie lymph node dissection in unresectable colorectal cancer with synchronous peritoneal metastasis: a propensity score analysis of data from a multi-institute database
verfasst von
Tomohisa Furuhata
Kenji Okita
Toshihiko Nishidate
Koichi Hirata
Hirofumi Ohnishi
Hirotoshi Kobayashi
Kenjiro Kotake
Kenichi Sugihara
Study Group for Peritoneal Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum
Publikationsdatum
01.10.2015
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 5/2015
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-015-0815-6

Weitere Artikel der Ausgabe 5/2015

International Journal of Clinical Oncology 5/2015 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.